July 9, 2019 / 5:09 AM / 3 months ago

BRIEF-Roche Presents Data For Hemlibra At ISTH 2019 Congress

July 9 (Reuters) - Roche Holding AG:

* NEW ANALYSES FROM PHASE III HAVEN STUDIES SUPPORT HEMLIBRA’S SUSTAINED EFFICACY, SAFETY AND QUALITY OF LIFE BENEFIT IN PEOPLE WITH HAEMOPHILIA A, WITH AND WITHOUT FACTOR VIII INHIBITORS

* FIRST DATA OF PHASE IIIB STASEY STUDY REINFORCES SAFETY PROFILE OF HEMLIBRA SEEN IN PIVOTAL HAVEN 1 CLINICAL TRIAL

* NEW ANALYSIS OF PIVOTAL DATA SUGGESTS ADDITIONAL FACTOR TREATMENT MAY NOT BE NEEDED FOR PEOPLE ON HEMLIBRA UNDERGOING CERTAIN MINOR SURGERY Source text for Eikon: [tinyurl.com/yy4gjzzd] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below